Clinical trials: Segmental Vitiligo
Patients With Active Non-segmental Vitiligo., Evaluation of the Efficacy of UVB and Fluticason Proprionate 0.05%
Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo
Rationale: Vitiligo vulgaris is a common acquired pigment disorder, which is characterised by the development of depigmented macules. It develops probably due to immunedestruction of melanocytes.
- Conditions
- Patients With Active Non-segmental Vitiligo., Evaluation of the Efficacy of UVB and Fluticason Proprionate 0.05%, Cream Compared to NB-UVB Alone in Patients With Non-segmental Vitiligo
- Trial name
- NCT01246921
- Testing
- Fluticasone proprionate 0.05% cream
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Non-segmental Vitiligo
The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo
The aim of this study is to evaluate the influence of simvastatin and atorvastatin on vitiligous lesions in patients with non-segmental vitiligo.
- Trial name
- EVRAAS (NCT03247400)
- Testing
- 1% simvastatin-acid sodium salt ointment, 1% atorvastatin calcium salt ointment
- Where
- Poland
- Volunteers
- 24 people
- Sponsor
- Nicolaus Copernicus University
Non-segmental Vitiligo
The Evaluation of Vitiligous Lesions Repigmentation After Topical Administration of Methotrexate in Patients With Active Vitiligo
The aim of this study is to evaluate the influence of two concentrations of methotrexate on vitiligous lesions in patients with non-segmental vitiligo
- Trial name
- EVRAM (NCT04942860)
- Testing
- 1% Methotrexate gel, 0.5% Methotrexate gel
- Where
- Poland
- Volunteers
- 25 people
- Sponsor
- Nicolaus Copernicus University
Vitiligo
Resident Memory T Cells in Vitiligo
This study aims to detect the presence and diversity of Tissue resident memory T cell populations in early and late cases of generalized non-segmental Vitiligo.
- Trial name
- NCT05223738
- Where
- Egypt
- Volunteers
- 29 people
- Sponsor
- Kasr El Aini Hospital
Non-segmental Vitiligo, Vitiligo
ReNovaCell in Non-segmental Vitiligo
Rationale: Autologous epidermal cell suspension grafting is an effective method of surgical treatment in vitiligo, which is suitable for treating large areas with good cosmetic results.
- Trial name
- NCT03022019
- Testing
- ReNovaCell
- Where
- Netherlands
- Volunteers
- 17 people
- Sponsor
- Netherlands Institute for Pigment Disorders
Skin and Connective Tissue Diseases, Skin Diseases
Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo
Vitiligo is a common acquired depigmentation disorder affecting approximately 2% of the world population. The purpose of this pilot study is to evaluate the effect and the safety of Tildrakizumab in adult participants with…
- Conditions
- Skin and Connective Tissue Diseases, Skin Diseases, Pigmentation Disorder, Hypopigmentation
- Trial name
- TILDVIT-1227 (NCT04971200)
- Testing
- Tildrakizumab
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- Premier Specialists, Australia
Vitiligo
Fractional Laser in Combination With UVB Therapy in Vitiligo Patients
Rationale: Vitiligo is a common skin disorder that can impair a patient's quality of life. Many depigmented lesions in vitiligo patients remain therapy resistant for medical treatment.
- Trial name
- NCT02290717
- Testing
- Fractional CO2 laser, NB-UVB therapy, Fluticasone Propionate Cream 0.05%
- Where
- Netherlands
- Sponsor
- Netherlands Institute for Pigment Disorders
Vitiligo, Secukinumab
Secukinumab in Active Non-segmental Vitiligo
Vitiligo is an acquired autoimmune skin disorder which leads to cutaneous depigmentations. A lot of progress has been made to unravel the pathophysiology of vitiligo.
- Trial name
- NCT05676333
- Testing
- Secukinumab
- Where
- Belgium
- Volunteers
- 8 people
- Sponsor
- University Hospital, Ghent
Pigmentation Disorders, Vitiligo
Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control
Tacrolimus ointment 0.1% has shown promising results for treating vitiligo in many prospective studies. Prospective randomized studies versus placebo are required to confirm the hypothesis that maintenance treatment with two…
- Trial name
- NCT01841008
- Testing
- Protopic
- Where
- 2 sites in France
- Volunteers
- 35 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Non-segmental Vitiligo
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)
- Trial name
- NCT07105254
- Testing
- Roflumilast topical 0.3% foam
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Derm Texas, PLLC
Active Non Segmental Vitiligo
Effect of NB-UVB on the Tissue Level of IL 15 and IL-15Rα in Active Non Segmental Vitiligo Cases.
This study aims at evaluating the effect of NB-UVB on tissue level of IL-15 and IL-15 receptor alpha subunit (IL-15Rα)(CD215) in active non segmental vitiligo.
- Trial name
- NCT05316987
- Testing
- Narrow band ultraviolet B
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Cairo University
Non-segmental Vitiligo
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not…
- Trial name
- NCT04052425
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 57 sites in United States, Bulgaria and 6 more
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation
Non-segmental Vitiligo
Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation
The aim of the study is to evaluate the efficacy of different lines of therapies on the TWEAK serum level in patients with non-segmental vitiligo.
- Trial name
- NCT04811326
- Testing
- NB-UVB, Latanoprost
- Where
- Egypt
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Shaimaa Fawzy Abdel-rady Abdel-latif
Non-segmental Vitiligo
A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo
The study is being conducted to evaluate the efficacy, and safety of SHR0302 tablets as single therapy or in combination with SHR0302 Base gel for patients with non-segmental vitiligo.
- Trial name
- NCT07251595
- Testing
- SHR0302 Tablets, SHR0302 Base Gel
- Where
- China
- Volunteers
- 176 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Vitiligo
Assessment of Hypoxia Inducible Factor and Autophagy Related Genes in Patients With Non-Segmental Vitiligo
The present study will aim to evaluate: 1. The presence of Hypoxia Inducible Factor in vitiligo patient 2. Defect of Autophagy Related Genes in vitiligo patient 3.
- Trial name
- NCT06410898
- Testing
- Punch Biopsy 5mm
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sohag University
Non Segmental Vitiligo
ICP-332 in Subjects With Non-segmental Vitiligo
This a phase II/III randomized, double-blind, placebo-controlled, parallel group, adaptive design, multi-center study to evaluate the efficacy and safety of ICP-332 in subjects with non-segmental vitiligo。The study consisted an…
- Trial name
- NCT07047612
- Testing
- ICP-332 Tablets
- Where
- 45 sites in China
- Volunteers
- 603 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Vitiligo
Effect of Procedural Variables on Outcome of Surgical Treatment of Vitiligo
ORSHFS grafts yielded lower cell counts than NCECS but the M-K ratio and resultant repigmentation did not show significant difference with better healing of the donor site.
- Trial name
- NCT02510651
- Testing
- Melanocyte-keratinocyte suspension
- Volunteers
- 40 people
- Sponsor
- Cairo University
Non-segmental Vitiligo, Segmental Vitiligo
Punchgrafting Techniques for Vitiligo
Rationale: Punch grafting is a safe, simple and widely used technique for in vitiligo. However, no reliable data are available on the effect of punch depth and punch size.
- Conditions
- Non-segmental Vitiligo, Segmental Vitiligo, Piebaldism
- Trial name
- MiniSNIP (NCT01377077)
- Testing
- punchgrafting
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Vitiligo Vulgaris
Possible Augmentation Of NB-UVB Induced Pigmentation In NSV By Carboxy.
Patients with stable vitiligo with 2 or more symmetric patches, 2 on acral sites and/or 2 on non acral sites will be recruited and assessed for eligibility for inclusion to receive NB-UVB on the whole body, and carboxytherapy on…
- Trial name
- NB-UVB (NCT07563049)
- Testing
- NB-UVB alone, NB-UVB combined with carboxy
- Where
- Egypt
- Volunteers
- 59 people
- Sponsor
- Kasr El Aini Hospital
Non-segmental Vitiligo
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
The primary purpose of this study is to evaluate whether the drug EI-001 can help improve vitiligo symptoms. EI-001 is a novel antibody drug that affects the immune system to decrease uncontrolled inflammation.
- Trial name
- NCT07223229
- Testing
- EI-001
- Where
- 6 sites in United States, Taiwan
- Volunteers
- 45 people
- Sponsor
- Elixiron Immunotherapeutics (Hong Kong) Ltd.